{"id":536235,"date":"2021-09-09T08:03:59","date_gmt":"2021-09-09T12:03:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"modified":"2021-09-09T08:03:59","modified_gmt":"2021-09-09T12:03:59","slug":"selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","title":{"rendered":"Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WATERTOWN, Mass., Sept.  09, 2021  (GLOBE NEWSWIRE) &#8212; Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR\u2122 platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta\u2019s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23<sup>rd<\/sup> Annual Global Investment Conference to be held September 13-15, 2021.<\/p>\n<p>The presentation will be available on-demand through the H.C. Wainwright <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=H4-xVXWTKSx_lJq8QYSB-J4A97LzpdxH07RzEoEmoGy3mfztIKXHgzRX07gfRiHVrPgTkLtIEo7ByVbpKs3HeWmRHEP6pW9y1n9DmJZ9rFWwvoYf6QViSKiyTDgnweUWeTTggrL4js_22-Ts8z8FQg==\" rel=\"nofollow noopener\" target=\"_blank\">conference portal<\/a>, starting at 7:00 a.m. ET on Monday, September 13, 2021.<\/p>\n<p>An archived webcast of the presentation will be accessible in the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z_1FpgI-CCo9GTE1r6-EDbQubQKvg81xPCqY_gRkgBMOlPDmtGAVeLw3VszUQU-2pRGrz3Ef9nkOScfqP8F2P1JqAKEXaraqrgjsuC-FjXY=\" rel=\"nofollow noopener\" target=\"_blank\">Investors &amp; Media<\/a> section of the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zf5e7RyCn_SR7xCk2a-3dxxmPJv0y1VpY1It86uzylR8Ee-ONwC1l7LfI_S2KQUG47LlTy91DlG9WzZMiEQXEupif-MNm5ntGuBYL16jBlc=\" rel=\"nofollow noopener\" target=\"_blank\">www.selectabio.com<\/a>.<\/p>\n<p>\n        <strong>About\u00a0Selecta Biosciences, Inc.<\/strong><br \/>\n        <br \/>Selecta Biosciences Inc.\u00a0(NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR\u2122 platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body\u2019s natural self-tolerance in autoimmune diseases.\u00a0Selecta\u00a0has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases.\u00a0Selecta Biosciences\u00a0is headquartered in the\u00a0Greater Boston\u00a0area. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zf5e7RyCn_SR7xCk2a-3d0LHXXv0LRqSzLyi7sk_Huy5LS9gqe-qgL1TJViokomYbQ6SOOMYF3ubEaCrGSIFdG-i5g7cWIyliFNWOzw-8HI=\" rel=\"nofollow noopener\" target=\"_blank\">www.selectabio.com<\/a>.<\/p>\n<p>\n        <strong>For Investors:<\/strong><br \/>\n        <br \/>Bruce Mackle<br \/>LifeSci Advisors, LLC<br \/>+1-929-469-3859<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rUVwLO7k9hXyoYCRnM8zUg6kNo_kiBoa5bHJoCsfbGl-5VPHZ-Vv6dtEPEnED-1UxW6rPO-wiXTiHgsiefSZ_288FOtwfi8TT6E7MUvZL1l837OdSnpFH2SFG7D9TQlV\" rel=\"nofollow noopener\" target=\"_blank\">bmackle@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>For Media:\u00a0<\/strong><br \/>\n        <br \/>Brittany Leigh, Ph.D.<br \/>LifeSci Communications, LLC<br \/>+1-646-751-4366<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fsDUp9K55rmyw7jMTTb7r7dexcD6NNQGrglm0rJufFobdgjuBDr-IPwmvLIxyp0KWP3DX220DMtxQLQMCXXi2ZE_TSUJKfG2cpHjrUeAtSs=\" rel=\"nofollow noopener\" target=\"_blank\">bleigh@lifescicomms.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNTMyMyM0Mzc1MzkxIzUwMDA3NjYxMA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjM2NWEyYzgtYTQ1NS00ZTk2LWFhY2EtODE5OWY0ZDMwNDJmLTUwMDA3NjYxMA==\/tiny\/Selecta-Biosciences-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR\u2122 platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta\u2019s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021. The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7:00 a.m. ET on Monday, September 13, 2021. An archived webcast of the presentation will be accessible in the Investors &amp; Media section of the company\u2019s website at www.selectabio.com. About\u00a0Selecta Biosciences, Inc. Selecta Biosciences Inc.\u00a0(NASDAQ: SELB) is a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-536235","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR\u2122 platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta\u2019s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021. The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7:00 a.m. ET on Monday, September 13, 2021. An archived webcast of the presentation will be accessible in the Investors &amp; Media section of the company\u2019s website at www.selectabio.com. About\u00a0Selecta Biosciences, Inc. Selecta Biosciences Inc.\u00a0(NASDAQ: SELB) is a &hellip; Continue reading &quot;Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-09T12:03:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNTMyMyM0Mzc1MzkxIzUwMDA3NjYxMA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference\",\"datePublished\":\"2021-09-09T12:03:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"wordCount\":259,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxNTMyMyM0Mzc1MzkxIzUwMDA3NjYxMA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"name\":\"Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxNTMyMyM0Mzc1MzkxIzUwMDA3NjYxMA==\",\"datePublished\":\"2021-09-09T12:03:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxNTMyMyM0Mzc1MzkxIzUwMDA3NjYxMA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxNTMyMyM0Mzc1MzkxIzUwMDA3NjYxMA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","og_description":"WATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR\u2122 platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta\u2019s Chief Executive Officer, Carsten Brunn, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021. The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7:00 a.m. ET on Monday, September 13, 2021. An archived webcast of the presentation will be accessible in the Investors &amp; Media section of the company\u2019s website at www.selectabio.com. About\u00a0Selecta Biosciences, Inc. Selecta Biosciences Inc.\u00a0(NASDAQ: SELB) is a &hellip; Continue reading \"Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-09T12:03:59+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNTMyMyM0Mzc1MzkxIzUwMDA3NjYxMA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference","datePublished":"2021-09-09T12:03:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"wordCount":259,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNTMyMyM0Mzc1MzkxIzUwMDA3NjYxMA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","name":"Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNTMyMyM0Mzc1MzkxIzUwMDA3NjYxMA==","datePublished":"2021-09-09T12:03:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNTMyMyM0Mzc1MzkxIzUwMDA3NjYxMA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNTMyMyM0Mzc1MzkxIzUwMDA3NjYxMA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=536235"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536235\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=536235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=536235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=536235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}